ASH 2023 | ASTX727 + a molecularly-targeted agent as personalized maintenance therapy in patients with AML
Tapan Kadia
• 14 Dec 2023
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the first data from a Phase Ib study (NCT05010772) evaluating an oral maintenance regimen composed of a decitabine/cedazuridine (ASTX727) backbone combined with a molecularly-targeted agent (venetoclax, gilteritinib, ivosidenib, or enasidenib). The early relapse-free survival (RFS) and overall survival (OS) results are encouraging, with further enrollment and follow-up planned. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
